Latest Breaking News On - Dupilumab dupixent - Page 1 : comparemela.com

Biologics for Severe Asthma Present Opportunities for Pharmacists

Drug therapy workups may reveal candidates for immune therapy and provide chance for interventions.

United statesUnited kingdomBenralizumab fasenraOmalizumab xolairRegeneron sanofiMepolizumab nucalaReslizumab cinqairDupilumab dupixentTeva respiratoryGlobal asthma initiativeGlobal initiative for asthmaMost recent national asthma dataPrevention programExpert panelGenentech incNational asthma education

Dementia Scotland: Blood test could predict dementia up to 15 years before diagnosis, study shows

Dementia Scotland: Blood test could predict dementia up to 15 years before diagnosis, study shows
scotsman.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scotsman.com Daily Mail and Mail on Sunday newspapers.

United kingdomScott muirCabozantinib cabometyxDupilumab dupixentRichard oakleyJianfeng fengSimon dawsonNilima marshallAdam stachuraAlzheimer societyFudan universityScottish medicines consortiumUniversity of warwickAlzheimer research united kingdomUniversity of warwick departmentNature aging

Q&A: Improved outcomes anticipated with dupilumab for children with EoE

Q&A: Improved outcomes anticipated with dupilumab for children with EoE
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Dupilumab dupixentEvans dellonSchool of medicineEsophageal diseases

Gastroenterology Month in Review: January 2024

Our January 2024 Month in Review spotlights the FDA approval of a new indication of dupilumab (Dupixent) for pediatric eosinophilic esophagitis, new clinical trial data, and research about the prevention and management of IBD.

Evan dellonDupilumab dupixentJulie khlevnerDrug administrationUniversity of north carolina chapel hillContemporary pediatricEsophageal diseasesNorth carolina chapel hillPediatric gastrointestinal motility centerColumbia university medical centerInflammatory bowel diseaseEosinophilic esophagitisUlcerative colitis

FDA Approves Dupilumab to Treat EoE for Children Under 12 Years

The expanded indication makes dupilumab the only approved treatment for eosinophilic esophagitis (EoE) in this age group.

United statesDupilumab dupixentGeorged yancopoulosNaimish patelHead of global developmentPediatric eoeSymptom questionnaire caregiverGlobal developmentAmerican journalEosinophilic esophagitisFda approval